BIOCERA-VET® Is Now Available for the Management of Dental and Orthopedics Conditions in Horses
13 March 2024 - 5:30PM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a
pioneering company in the management of osteoarticular diseases in
pets, announces the launch of BIOCERA-VET® Equine in countries
already covered by the Company.
After being assessed by equine vets in orthopedic and dental
applications over the past 12 months, BIOCERA-VET® is now available
on the market with 2 additional references (3cc and 6cc)
specifically adapted in terms of volume and devices for equine
applications.
BIOCERA-VET® has an exclusive positioning in the treatment of
subchondral bone cysts, thanks to the properties - that only
BIOCERA-VET® offers today on the market - required for minimally
invasive cementoplasty (high injectability, long workability,
high radiopacity, high cohesiveness and fast
self-setting).
The subchondral bone cysts affect 25% of yearlings (horses in
their second year), representing 200,000 horses in Europe and in
the United States and common cause of lameness and reduced
performance of young equine athletes. BIOCERA-VET® will also be
used as innovative treatment in dental applications and
oral/maxillofacial surgery (damage to the alveolar bone, delayed
alveolar granulation or orosinus fistulation, common complications
after tooth extraction).
About TheraVet SA
TheraVet is a veterinary biotechnology company specializing in
osteoarticular treatments for companion animals. The Company
develops targeted, safe and effective treatments to improve the
quality of life of pets suffering from joint and bone diseases. For
pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, has its head office
in Belgium (Gosselies) with a US subsidiary.
For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter
About BIOCERA-VET®
In close collaboration with an international scientific board,
THERAVET has developed a new line of calcium-phosphate and
biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full
range of innovative, easy-to-use, efficient & cost-effective
bone substitutes indicated in bone surgeries where a bone graft is
required and as a palliative alternative in the management of
canine osteosarcoma. Based on extremely promising clinical results,
this line offers the possibility of a better, more convenient and
more efficient orthopedic surgery.
BIOCERA-VET® is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240312135080/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94 Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33
(0)1 44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Apr 2024 to May 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From May 2023 to May 2024